Evaluation of mimimally invasive palliative therapy by Transcatheter arterial chemoembolization for unresectable recurrent head and neck cancer

Evaluation of mimimally invasive palliative therapy by Transcatheter arterial chemoembolization for unresectable recurrent head and neck cancer - Evaluation of TACE for unresectable recurrent head and neck cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007373

Enrollment

Registered

2012-02-24

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer

Interventions

TACE

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Patient age 20 years and above 2, unresectable recurrent head and neck cancer after common therapy 3, bleeding for cutaneous and mucosal invasion or high risk of bleeding 4, no other effective treatment 5, Patients who were provided written informed consent

Exclusion criteria

Exclusion criteria: 1, pregnancy or lactating women or women with suspected pregnancy 2, possibility of the remarkabke phisical damage by this treatment 3, Patient judged by the investigator to be unfit to be enrolled into the study

Design outcomes

Primary

Measure	Time frame
efficacy of hemostasis, duration of hemostasis, duration of hospitalization after treatment, pain control,	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026